Elicera Therapeutics AB (publ) announced that its co-founder, Professor Magnus Essand, has received a total of 4.8 MSEK in funding from the Swedish Childhood Cancer Fund. The research project, which spans over three years, will be conducted by professor Magnus Essand's research group at Uppsala University and aims to investigate the ability of CAR T-cells to induce immunity in brain tumors in children. The research grant from the Swedish Childhood Cancer Fund is awarded to Uppsala University, and the results generated in the project will contribute to the understanding of whether Elicera's cell therapy candidate ELC-401 could also be used in the future to treat brain tumors in children.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.932 SEK | -0.85% | -12.49% | -79.56% |
03-28 | Elicera Therapeutics AB Announces Director Changes | CI |
03-06 | Elicera Enters Agreement with Prominent US Cancer Center to Evaluate the Use of ITANK in T-Cell Receptor Therapies | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-79.56% | 3.07M | |
+38.51% | 727B | |
+33.05% | 599B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+16.00% | 243B | |
+8.09% | 205B | |
-5.77% | 203B | |
+6.19% | 164B |
- Stock Market
- Equities
- ELIC Stock
- News Elicera Therapeutics AB
- Elicera Therapeutics AB Co-Founder Receives Grant Totalling 4.8 million SEK from the Swedish Childhood Cancer Fund to Support Car T-Cell Research